查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842299

美國醫藥CDMO市場：市場規模、佔有率和趨勢分析（按類型、產品、服務、工作流程、治療領域和最終用途分類），細分市場預測（2025-2033年）

U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Type, By Product, By Services, By Workflow, By Therapeutic Area, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國製藥CDMO市場概覽

據估計，2024 年美國藥品 CDMO 市值為 365 億美元，預計到 2033 年將達到 653 億美元，2025 年至 2033 年的複合年成長率為 6.74%。

美國製藥 CDMO（合約開發和生產組織）產業蓬勃發展，這得益於生技藥品、生物相似藥和先進療法的成長，藥物開發外包需求的增加，臨床試驗活動的活性化以及研發管線的擴展。

美國市場在生技藥品、生物相似藥以及先進的細胞和基因療法方面正經歷顯著成長，從而推動了對專業CDMO服務的需求。這些療法的研發和生產需要先進的能力，例如一次性生物製程系統、病毒載體生產以及個人化醫療方面的專業知識，而許多製藥公司並不具備這些能力。

CDMO（合約研發生產機構）提供基礎設施、監管知識和創新平台，以加速產品開發並符合FDA標準。隨著越來越多的生技藥品和生物相似藥在美國核准，CDMO已成為擴大生產規模、確保供應鏈韌性以及加速複雜、高價值治療藥物上市速度的關鍵合作夥伴。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章：美國醫藥CDMO市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
  • 研發費用分析
  • 產業生態系分析
    • 需求分析
    • 供應鏈分析
  • 技術格局
  • 臨床實驗數量分析（2024 年）
  • 定價分析
  • 分析關稅和貿易協定的影響
  • 價值鏈分析
    • 供應趨勢
    • 需求趨勢
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析與SWOT分析

第4章：美國醫藥CDMO市場：按類型分類的估算與趨勢分析

  • 美國醫藥CDMO市場：按類型分類的概覽
  • 美國醫藥CDMO市場：按類型分類的變化分析
  • 按類型（2021-2033 年）
  • 低分子
    • 品牌
    • 非專利的
  • 聚合物
    • 生物製藥
    • 生物相似藥

第5章：美國醫藥CDMO市場：按產品分類的估算與趨勢分析

  • 美國製藥CDMO市場：產品概覽
  • 美國醫藥CDMO市場：按產品分類的變化分析
  • 按類型（2021-2033 年）
  • API（原料藥）
    • 傳統 API
    • 高活性原料藥（HP-API）
    • 生技藥品
    • 其他
  • 製藥
    • 口服固態劑型
    • 半固態
    • 液體劑型
    • 其他

第6章：美國醫藥CDMO市場：按服務類型分類的估算與趨勢分析

  • 美國醫藥CDMO市場：按服務分類的概覽
  • 美國醫藥CDMO市場：按服務類型分類的變化分析
  • 依服務年資（2021-2033）
  • 合約開發
    • 預配方和配方開發服務
    • 製程開發與最佳化
    • 分析測試和方法檢驗
    • 規模化和技術轉移
  • 契約製造
    • API生產
    • 成品藥生產
  • 包裝和標籤
  • 監管事務
  • 其他

第7章：美國製藥CDMO市場：依工作流程分類的估算與趨勢分析

  • 美國製藥CDMO市場：工作流程儀錶板
  • 美國製藥CDMO市場：按工作流程分類的差異分析
  • 按工作流程（2021-2033）
  • 臨床
  • 上市

第8章：美國醫藥CDMO市場：依治療領域分類的估算與趨勢分析

  • 美國製藥CDMO市場：治療領域概覽
  • 美國製藥CDMO市場：按治療領域分類的變化分析
  • 依治療領域分類（2021-2033 年）
  • 瘤
  • 感染疾病
  • 神經系統疾病
  • 心血管疾病
  • 代謝紊亂
  • 自體免疫疾病
  • 呼吸系統疾病
  • 眼科
  • 胃腸道疾病
  • 整形外科疾病
  • 牙科疾病
  • 其他

第9章：美國醫藥CDMO市場：依最終用途分類的估算與趨勢分析

  • 美國醫藥CDMO市場：按最終用途分類的概覽
  • 美國醫藥CDMO市場：依最終用途分類的變化分析
  • 依最終用途分類（2021-2033 年）
  • 小型製藥公司
  • 中型製藥公司
  • 大型製藥企業

第10章 競爭格局

  • 主要參與企業的分類
    • 市場領導
    • 新興企業
  • 市佔率/估值分析（熱力圖分析），2024 年
  • 公司簡介
    • Thermo Fisher Scientific, Inc
    • Lonza
    • Recipharm AB
    • Catalent, Inc
    • WuXi AppTec, Inc
    • Samsung Biologics
    • Piramal Pharma Solutions
    • Siegfried Holding AG
    • Corden Pharma International
    • Cambrex Corporation
    • Vetter Pharma
    • Delpharm
    • Jubilant Pharmova/HollisterStier
    • Eurofins CDMO
    • Almac Pharma Services
Product Code: GVR-4-68040-754-9

U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Summary

The U.S. pharmaceutical contract development and manufacturing organization market size was estimated at USD 36.5 billion in 2024 and is projected to reach USD 65.3 billion by 2033, growing at a CAGR of 6.74% from 2025 to 2033. The U.S. pharmaceutical contract development & manufacturing organization (CDMO) is advancing, driven by the growth of biologics, biosimilars, and advanced therapies, rising demand for outsourcing in drug development, and increasing clinical trial activity and pipeline expansion.

The U.S. market is witnessing significant growth in biologics, biosimilars, and advanced cell and gene therapies, fueling demand for specialized CDMO services. Developing and manufacturing these therapies requires advanced capabilities like single-use bioprocessing systems, viral vector production, and personalized medicine expertise, which many pharma companies lack in-house.

CDMOs provide infrastructure, regulatory knowledge, and innovation platforms to accelerate development while meeting FDA standards. With rising approvals of biologics and biosimilars in the U.S., CDMOs are becoming indispensable partners in scaling production, ensuring supply chain resilience, and enabling faster time-to-market for complex, high-value therapeutics.

U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pharmaceutical CDMO market report based on type, product, service, workflow, therapeutic area, and end use:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecule
    • Branded
    • Generic
  • Large Molecule
    • Biologics
    • Biosimilar
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • API
    • Traditional Active Pharmaceutical Ingredient (Traditional API)
    • Highly Potent Active Pharmaceutical Ingredient (HP-API)
    • Biologics
    • Others
  • Drug Product
    • Oral solid dose
    • Semi-solid dose
    • Liquid dose
    • Others
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Development
    • Pre-formulation & Formulation Development Services
    • Process Development & Optimization
    • Analytical Testing & Method Validation
    • Scale-up & Tech Transfer
  • Contract Manufacturing
    • API Manufacturing
    • Finished Drug Products Manufacturing
  • Packaging and Labelling
  • Regulatory Affairs
  • Others
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disease
  • Metabolic Disorders
  • Autoimmune Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Gastrointestinal Disorders
  • Orthopedic Diseases
  • Dental Diseases
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Pharmaceutical Companies
  • Medium Pharmaceutical Companies
  • Large Pharmaceutical Companies

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Services
    • 1.2.4. Workflow
    • 1.2.5. Therapeutic Area
    • 1.2.6. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Botton-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
  • 3.3. R&D Spending Analysis
  • 3.4. Industry Ecosystem Analysis
    • 3.4.1. Demand Analysis
    • 3.4.2. Supply Chain Analysis
  • 3.5. Technology Landscape
  • 3.6. Clinical Trial Volume Analysis, 2024
  • 3.7. Pricing Analysis
  • 3.8. Tariff and Trade Agreement Impact Analysis
  • 3.9. Value Chain Analysis
    • 3.9.1. Supply Trends
    • 3.9.2. Demand Trends
  • 3.10. Market Analysis Tools
    • 3.10.1. Porter's Five Forces Analysis
    • 3.10.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
  • 4.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
  • 4.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Branded
      • 4.4.2.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Generic
      • 4.4.3.1. Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Biologics
      • 4.5.2.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Biosimilar
      • 4.5.3.1. Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
  • 5.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
  • 5.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
  • 5.4. API
    • 5.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
      • 5.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
      • 5.4.3.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Biologics
      • 5.4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Drug Product
    • 5.5.1. Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Oral Solid Dose
      • 5.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Semi-Solid Dose
      • 5.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. Liquid Dose
      • 5.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Others
      • 5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis

  • 6.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
  • 6.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
  • 6.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 6.4. Contract Development
    • 6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Pre-formulation & Formulation Development Services
      • 6.4.2.1. Pre-formulation & Formulation Development Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Process Development & Optimization
      • 6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Analytical Testing & Method Validation
      • 6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Scale-up & Tech Transfer
      • 6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Contract Manufacturing
    • 6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. API Manufacturing
      • 6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Finished Drug Products Manufacturing
      • 6.5.3.1. Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Packaging and Labelling
    • 6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Regulatory Affairs
    • 6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis

  • 7.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
  • 7.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
  • 7.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
  • 7.4. Clinical
    • 7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Commercial
    • 7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
  • 8.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
  • 8.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
  • 8.4. Oncology
    • 8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Infectious Diseases
    • 8.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Neurological Disorders
    • 8.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Cardiovascular Diseases
    • 8.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Metabolic Disorders
    • 8.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Autoimmune Diseases
    • 8.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Respiratory Diseases
    • 8.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.11. Ophthalmology
    • 8.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.12. Gastrointestinal Disorders
    • 8.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.13. Orthopedic Diseases
    • 8.13.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.14. Dental Diseases
    • 8.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.15. Others
    • 8.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: End Use Estimates & Trend Analysis

  • 9.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Segment Dashboard
  • 9.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Movement Analysis
  • 9.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 9.4. Small Pharmaceutical Companies
    • 9.4.1. Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medium Pharmaceutical Companies
    • 9.5.1. Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Large Pharmaceutical Companies
    • 9.6.1. Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Key Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 10.3. Company Profiles
    • 10.3.1. Thermo Fisher Scientific, Inc
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Lonza
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Recipharm AB
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Catalent, Inc
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. WuXi AppTec, Inc
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Samsung Biologics
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Piramal Pharma Solutions
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Siegfried Holding AG
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Corden Pharma International
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Cambrex Corporation
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Vetter Pharma
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Delpharm
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Jubilant Pharmova / HollisterStier
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Eurofins CDMO
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives
    • 10.3.15. Almac Pharma Services
      • 10.3.15.1. Company Overview
      • 10.3.15.2. Financial Performance
      • 10.3.15.3. Service Benchmarking
      • 10.3.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 5 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 7 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 8 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Type outlook and key takeaways
  • Fig. 20 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Type movement analysis
  • Fig. 21 Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Product outlook and key takeaways
  • Fig. 28 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Product movement analysis
  • Fig. 29 Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Traditional API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 HP-API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Service outlook and key takeaways
  • Fig. 41 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Service movement analysis
  • Fig. 42 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Pre-formulation & Formulation Development Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow outlook and key takeaways
  • Fig. 54 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow movement analysis
  • Fig. 55 Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area outlook and key takeaways
  • Fig. 58 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area movement analysis
  • Fig. 59 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: End Use outlook and key takeaways
  • Fig. 72 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: End Use movement analysis
  • Fig. 73 Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key company categorization
  • Fig. 77 Service heat map analysis
  • Fig. 78 Strategic framework